Synapsoft logo
AI Insights from Disclosures
Searching...
ABL Bio Inc. 298380
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
ABL Bio Inc. pursues a business model capable of mid-to-long-term growth through the licensing-out of various pipelines that it researches and develops based on its core technology, the bispecific antibody platform 'Grabody™'. The company accelerates its development speed by adding the capabilities of research and development partners to its core technology and pipelines, while applying a strict Decision Review System for determining whether to proceed further, boldly discontinuing development early for technologies with limited potential for value increase, thereby pursuing high value creation relative to total development costs.
Representative Director Lee Sanghun
Founded February 16, 2016
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 11011-5974020
Business number 452-88-00266
Phone Number 02-3456-7300
Fax Number 031-8018-9836
Website www.ablbio.com
Company Address 456 Bongeunsa-ro, Gangnam-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant